Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma.
Paul DanielBrian MeehanSiham SabriFatemeh JamaliJann N SarkariaDongsic ChoiDelphine GarnierGaspar KitangeKate I GlennonAntoine PaccardJason KaramchandaniYasser RiazalhosseiniJanusz RakBassam AbdulkarimPublished in: Neuro-oncology advances (2022)
Hypermutation post-TMZ are phenotypically distinct from non-hypermutant GBM and requires personalization for appropriate treatment. The brain microenvironment may be immunosuppressive and exploration of the mechanisms behind this may be key to improving immunotherapy response in this subtype of recurrent GBM.